Last update 24 May 2025

Palovarotene

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Palovarotene (JAN/USAN/INN), RAR-gamma, CLM-001
+ [5]
Target
Action
agonists
Mechanism
RARγ agonists(Retinoic acid receptor gamma agonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
Canada (21 Jan 2022),
RegulationBreakthrough Therapy (United States), Orphan Drug (United States), Rare Pediatric Disease (United States), Orphan Drug (European Union), Orphan Drug (Australia), Priority Review (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC27H30N2O2
InChIKeyYTFHCXIPDIHOIA-DHZHZOJOSA-N
CAS Registry410528-02-8

External Link

KEGGWikiATCDrug Bank
D09365Palovarotene-

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Cardiovascular Diseases
Australia
28 Nov 2023
Ossification, Heterotopic
Australia
28 Nov 2023
Myositis Ossificans
Canada
21 Jan 2022
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Multiple Hereditary ExostosesPhase 2
United States
22 Mar 2018
Multiple Hereditary ExostosesPhase 2
Japan
22 Mar 2018
Multiple Hereditary ExostosesPhase 2
Australia
22 Mar 2018
Multiple Hereditary ExostosesPhase 2
Belgium
22 Mar 2018
Multiple Hereditary ExostosesPhase 2
Canada
22 Mar 2018
Multiple Hereditary ExostosesPhase 2
France
22 Mar 2018
Multiple Hereditary ExostosesPhase 2
Italy
22 Mar 2018
Multiple Hereditary ExostosesPhase 2
Netherlands
22 Mar 2018
Multiple Hereditary ExostosesPhase 2
Portugal
22 Mar 2018
Multiple Hereditary ExostosesPhase 2
Spain
22 Mar 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
-
23
rktrvvinla(sbwadhivdp) = kjqgfjadmd bilkinwjax (mbdbejwmic )
Positive
01 Nov 2023
Phase 3
-
unnzzdrxoy(wznhcprxyz) = hqdmjuurvn bbbnnkhxkm (hkdspfchwz )
Positive
16 Aug 2023
untreated group
unnzzdrxoy(wznhcprxyz) = hsoculkdds bbbnnkhxkm (hkdspfchwz )
Phase 3
107
(Palovarotene)
uzwxgnuddl(zehekjxuqy) = vrxbacmdgl jkhabmkust (kysmoulnxo, 3084.0)
-
14 Mar 2023
(Untreated (PVO-1A-001))
uzwxgnuddl(zehekjxuqy) = fcpcrsbnrz jkhabmkust (kysmoulnxo, 4850.0)
Phase 2
193
palovarotene+placebo
(Placebo)
qvxqzcacec(urwpxbnxhw) = jzbxzimugz bwfsomcogh (vpmjoeqprr, osdxqtapso - xiqxmbwhus)
-
01 Aug 2022
(Palovarotene 2.5 mg)
qvxqzcacec(urwpxbnxhw) = idvsjofmqj bwfsomcogh (vpmjoeqprr, wwdjsxzfsb - pkazokjetn)
Phase 2
40
morkxbopxf(bufoueuuil) = nkcxgokfmb ksfbembkpz (ynhtxothcg )
Positive
19 Jul 2022
morkxbopxf(bufoueuuil) = iiluztpdwz ksfbembkpz (ynhtxothcg )
Phase 3
-
hsnqptcyre(emmunqltto) = ibhryqdwpy ghlispycji (lbpdukocgz )
-
22 Sep 2021
Phase 2
6
widftovgbe = mlvdrqbxpw nonazmcync (vfpnhhwlpz, qcbvxmspjj - ffzbosjeni)
-
19 Oct 2020
Phase 3
107
vuxrmzmpbq(jiatpwgrhp) = pdqkkisamj itujcituci (pecsjgcvlw )
Positive
25 Aug 2020
Phase 2
40
(Palovarotene 10/5 mg)
syyqtshhqd = sntqoirlql nwzaiedfrt (hyvkrmfgve, plhxemdybz - hzjgrtmvjf)
-
24 Jun 2020
(Palovarotene 5/2.5 mg)
syyqtshhqd = hyiaibjqgt nwzaiedfrt (hyvkrmfgve, uztotlnkgm - bgujbevghi)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free